Therapeutic strategies for eosinophilic dermatoses.

Simon, Dagmar; Simon, Hans-Uwe (2019). Therapeutic strategies for eosinophilic dermatoses. Current opinion in pharmacology, 46, pp. 29-33. Elsevier 10.1016/j.coph.2019.01.002

Text Simon_Therapeutic strategies for eosinophilic dermatoses.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (597kB)

Eosinophil infiltration is observed in a broad spectrum of skin diseases of various origins. Eosinophils are thought to actively contribute to pathogenesis as they are able to defend against microbes, to regulate inflammation, cause tissue damage, promote remodeling and fibrosis, and initiate pruritus. Therefore, targeting eosinophils would seem a worthwhile therapeutic approach. A promising strategy is to target the production, activation and survival of eosinophils, example with antibodies directed against IL-5 or its receptor, and Siglec-8. Dexpramipexole and tyrosine kinase inhibitors have been shown to reduce eosinophil numbers in patients with hypereosinophilia. Janus kinase inhibitors block signal transduction and thus activation of inflammatory cells including eosinophils. A further approach is to target cells and cytokines acting on or mediators released by eosinophils, for example, CD52, IL-13, IL-31, TSLP, and eotaxins. This review summarizes current therapeutic strategies, including novel agents affecting eosinophils directly that are under clinical investigation.

Interest & Impact

Downloads

2 since deposited on 23 Apr 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item